Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR,

Slides:

Advertisements

Similar presentations

Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing.

Advertisements

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to- severe plaque psoriasis up to 1 year: Results from the CLEAR study

Biphasic skin reactions during telaprevir-based therapy of Japanese patients infected with hepatitis C virus Akiko Kishi, MD, Nobukazu Hayashi, MD, PhD,

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: A randomized.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Use of Eczema Action Plans (EAPs) to improve parental understanding of treatment regimens in pediatric atopic dermatitis (AD): A randomized controlled.

Efficacy of simvastatin in plaque psoriasis: A pilot study

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Shawn G. Kwatra, BS, Hong Liang Tey, MRCP (UK), Saba M

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

OPA-15406, a novel, topical, nonsteroidal, selective phosphodiesterase-4 (PDE4) inhibitor, in the treatment of adult and adolescent patients with mild.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Treatment of notalgia paresthetica with botulinum toxin A: A double-blind randomized controlled trial Catherine Maari, MD, FRCPC, Philippe Marchessault,

Ana Corcimaru, BS, Dean S. Morrell, MD, Craig N. Burkhart, MD

Alopecia areata after dupilumab for atopic dermatitis

Effect of sequential applications of topical tacrolimus and topical corticosteroids in the treatment of pediatric atopic dermatitis: An open-label pilot.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Pilot study of a skin cancer education curriculum for medical students

Reply to: “A note on normality”

Clinical and photographic assessment of lichen planopilaris treatment efficacy Aline Donati, MD, Philipe Assouly, MD, Bruno Matard, MD, Corinne Jouanique,

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Increased serum levels of interleukin 33 in patients with atopic dermatitis Risa Tamagawa-Mineoka, MD, PhD, Yasutaro Okuzawa, MD, Koji Masuda, MD, PhD,

Topical calcipotriol before ablative fractional laser-assisted photodynamic therapy enhances treatment outcomes for actinic keratosis in Fitzpatrick grades.

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis.

Isotretinoin for high-grade or refractory epidermal growth factor receptor inhibitor-related acneiform papulopustular eruptions Herbert C. Chiang, MD,

Leflunomide as adjuvant treatment of dermatomyositis

Dema T. Alniemi, MD, Laura McGevna, MD JAAD Case Reports

Anjali Shroff, MD, Emma Guttman-Yassky, MD, PhD JAAD Case Reports

Efficacy and safety of dupilumab in perennial allergic rhinitis and comorbid asthma Steven F. Weinstein, MD, Rohit Katial, MD, Shyamalie Jayawardena,

Which Treatment Is Better

Stefan Tukaj, PhD, Detlef Zillikens, MD, Michael Kasperkiewicz, MD

Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants Roland Kaufmann, MD, Regina Fölster-Holst, MD, Peter Höger, MD,

Recalcitrant prurigo nodularis treated successfully with dupilumab

A comparison of postprocedural wound care treatments: Do antibiotic-based ointments improve outcomes? Zoe D. Draelos, MD, FAAD, Ronald L. Rizer, PhD,

Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by.

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial Sonja Ständer, MD, Paul Kwon, MD,

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Ulrich Mrowietz, MD, Hervé Bachelez, MD, PhD, A

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

Jennifer L. Hundley, MD, Christie L

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Ixekizumab treatment shows a neutral impact on cardiovascular parameters in patients with moderate-to-severe plaque psoriasis: Results from UNCOVER-1,

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Gordon W. Jung, MD, Patricia T. Ting, MSc, MD, Thomas G

Tezepelumab, an anti–thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a.

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Gaps in pain management in dermatology: A needs assessment from Canada

Alan Menter, MD, Stephen K

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Brian B. Johnson, MD, Lisa A. Beck, MD, S. Shahzad Mustafa, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Volume 5, Issue 7, Pages (July 2019)

Presentation transcript:

Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults Eric L. Simpson, MD, MCR, Thomas Bieber, MD, Laurent Eckert, PhD, Richard Wu, PhD, Marius Ardeleanu, MD, Neil M.H. Graham, MD, Gianluca Pirozzi, MD, PhD, Vera Mastey, MSc Journal of the American Academy of Dermatology Volume 74, Issue 3, Pages 491-498 (March 2016) DOI: 10.1016/j.jaad.2015.10.043 Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Atopic dermatitis. Frequency (days per week) of non-itch skin symptoms evaluated on the Patient-Oriented Eczema Measure. ∗Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology 2016 74, 491-498DOI: (10.1016/j.jaad.2015.10.043) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Atopic dermatitis. Impact of itch and atopic dermatitis on sleep, assessed using items on the 5-dimension (5-D) Pruritus Scale and the Patient-Oriented Eczema Measure (POEM). ∗Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology 2016 74, 491-498DOI: (10.1016/j.jaad.2015.10.043) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Atopic dermatitis. Impact of skin condition on items contributing to health-related quality of life as measured over the past week using the Dermatology Life Quality Index. ∗Impact of treatment was for therapies before randomization to treatment with dupilumab or placebo. †Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology 2016 74, 491-498DOI: (10.1016/j.jaad.2015.10.043) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions

Fig 4 Atopic dermatitis. Patient-reported effects on outcomes contributing to health-related quality of life: functional and participatory activities assessed on the 5-D Pruritus Scale (N = 379) (A) and dimensions of the 5-dimension EuroQol (B). ∗Percentages were calculated with N = 380 as the denominator. Journal of the American Academy of Dermatology 2016 74, 491-498DOI: (10.1016/j.jaad.2015.10.043) Copyright © 2015 American Academy of Dermatology, Inc. Terms and Conditions